SCHEMBL8310323

SCHEMBL8310323

Cc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2)c1-c1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 10/20 1.00
CNR2 P34972 5/20 0.76
CYP2C9 P11712 2/20 0.76
GPR55 Q9Y2T6 2/20 0.76
ABCC4 O15439 1/20 0.76
MLNR O43193 1/20 0.76
ABCB11 O95342 1/20 0.76
CHRM2 P08172 1/20 0.76
ADORA3 P0DMS8 1/20 0.76
ADRA2B P18089 1/20 0.76
ADRA2C P18825 1/20 0.76
DRD1 P21728 1/20 0.76
TBXA2R P21731 1/20 0.76
SLC6A2 P23975 1/20 0.76
HRH2 P25021 1/20 0.76
HTR2A P28223 1/20 0.76
AGTR1 P30556 1/20 0.76
CCKAR P32238 1/20 0.76
CCKBR P32239 1/20 0.76
MC4R P32245 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16197600 0.95 CNR1 (0.90) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL276640 0.94 CNR1 (0.88) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL24270315 0.93 CNR1 (0.88) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL277226 0.93 CNR1 (0.86) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL276798 0.92 CNR1 (0.85) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL276791 0.91 CNR1 (0.83) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL277078 0.91 CNR1 (0.83) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL277222 0.90 CNR1 (0.81) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL277014 0.89 CNR1 (0.80) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL277079 0.89 CNR1 (0.80) CNR1CNR2CYP2C9GPR55ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004078261-A1 CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) 2004-09-16 WO disclosed